Gilead Sciences Revenue 2006-2021 | GILD
For a detailed definition, formula and example for Revenue, check out our new background page here.
Gilead Sciences annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Gilead Sciences revenue for the quarter ending September 30, 2021 was $7.421B, a 12.83% increase year-over-year.
- Gilead Sciences revenue for the twelve months ending September 30, 2021 was $27.482B, a 18.73% increase year-over-year.
- Gilead Sciences annual revenue for 2020 was $24.689B, a 9.98% increase from 2019.
- Gilead Sciences annual revenue for 2019 was $22.449B, a 1.46% increase from 2018.
- Gilead Sciences annual revenue for 2018 was $22.127B, a 15.24% decline from 2017.
Gilead Sciences Annual Revenue
(Millions of US $) |
| 2020 |
$24,689 |
| 2019 |
$22,449 |
| 2018 |
$22,127 |
| 2017 |
$26,107 |
| 2016 |
$30,390 |
| 2015 |
$32,639 |
| 2014 |
$24,890 |
| 2013 |
$11,202 |
| 2012 |
$9,702 |
| 2011 |
$8,385 |
| 2010 |
$7,949 |
| 2009 |
$7,011 |
| 2008 |
$5,336 |
| 2007 |
$4,230 |
| 2006 |
$3,026 |
| 2005 |
$2,028 |
Gilead Sciences Quarterly Revenue
(Millions of US $) |
| 2021-09-30 |
$7,421 |
| 2021-06-30 |
$6,217 |
| 2021-03-31 |
$6,423 |
| 2020-12-31 |
$7,421 |
| 2020-09-30 |
$6,577 |
| 2020-06-30 |
$5,143 |
| 2020-03-31 |
$5,548 |
| 2019-12-31 |
$5,879 |
| 2019-09-30 |
$5,604 |
| 2019-06-30 |
$5,685 |
| 2019-03-31 |
$5,281 |
| 2018-12-31 |
$5,795 |
| 2018-09-30 |
$5,596 |
| 2018-06-30 |
$5,648 |
| 2018-03-31 |
$5,088 |
| 2017-12-31 |
$5,949 |
| 2017-09-30 |
$6,512 |
| 2017-06-30 |
$7,141 |
| 2017-03-31 |
$6,505 |
| 2016-12-31 |
$7,320 |
| 2016-09-30 |
$7,500 |
| 2016-06-30 |
$7,776 |
| 2016-03-31 |
$7,794 |
| 2015-12-31 |
$8,506 |
| 2015-09-30 |
$8,295 |
| 2015-06-30 |
$8,244 |
| 2015-03-31 |
$7,594 |
| 2014-12-31 |
$7,314 |
| 2014-09-30 |
$6,042 |
| 2014-06-30 |
$6,535 |
| 2014-03-31 |
$4,999 |
| 2013-12-31 |
$3,120 |
| 2013-09-30 |
$2,783 |
| 2013-06-30 |
$2,767 |
| 2013-03-31 |
$2,532 |
| 2012-12-31 |
$2,588 |
| 2012-09-30 |
$2,427 |
| 2012-06-30 |
$2,405 |
| 2012-03-31 |
$2,282 |
| 2011-12-31 |
$2,200 |
| 2011-09-30 |
$2,122 |
| 2011-06-30 |
$2,137 |
| 2011-03-31 |
$1,926 |
| 2010-12-31 |
$1,999 |
| 2010-09-30 |
$1,938 |
| 2010-06-30 |
$1,927 |
| 2010-03-31 |
$2,086 |
| 2009-12-31 |
$2,032 |
| 2009-09-30 |
$1,801 |
| 2009-06-30 |
$1,647 |
| 2009-03-31 |
$1,530 |
| 2008-12-31 |
$1,428 |
| 2008-09-30 |
$1,371 |
| 2008-06-30 |
$1,278 |
| 2008-03-31 |
$1,258 |
| 2007-12-31 |
$1,095 |
| 2007-09-30 |
$1,059 |
| 2007-06-30 |
$1,048 |
| 2007-03-31 |
$1,028 |
| 2006-12-31 |
$899 |
| 2006-09-30 |
$749 |
| 2006-06-30 |
$685 |
| 2006-03-31 |
$693 |
| 2005-12-31 |
$609 |
| 2005-09-30 |
$493 |
| 2005-06-30 |
$495 |
| 2005-03-31 |
$430 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$85.060B |
$24.689B |
|
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
|
